NICE backs stomach cancer, PAH drugs for NHS use
AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
Newsletters and Deep Dive digital magazine
AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
UK Health Secretary Wes Streeting has resigned from Keir Starmer's government, saying he has lost faith in the Prime Minister's leadership.
BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.
According to multiple press reports citing anonymous insider sources, Dr Marty Makary has resigned after a year at the head of the FDA.
Editor's Picks
Newsletters and Deep Dive
digital magazine